CL2021003057A1 - Formas cristalinas de un inhibidor btk - Google Patents
Formas cristalinas de un inhibidor btkInfo
- Publication number
- CL2021003057A1 CL2021003057A1 CL2021003057A CL2021003057A CL2021003057A1 CL 2021003057 A1 CL2021003057 A1 CL 2021003057A1 CL 2021003057 A CL2021003057 A CL 2021003057A CL 2021003057 A CL2021003057 A CL 2021003057A CL 2021003057 A1 CL2021003057 A1 CL 2021003057A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- crystal forms
- btk inhibitor
- diseases
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se refiere a varias formas cristalinas anhidras N–(3–(6–amino–5–(2–(N–metilacrilamido)etoxi)pirimidin–4–il)–5–fluoro–2–metilfenil)–4–ciclopropil–2–fluorobenzamida, así como composiciones, método de fabricación y sus métodos de uso. Estas formas cristalinas son útiles en el tratamiento de enfermedades y trastornos que típicamente se mejoran mediante la inhibición de BTK. Dichas enfermedades y trastornos pueden incluir trastornos inflamatorios y autoinmunes e inflamación pulmonar y del tracto respiratorio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851986P | 2019-05-23 | 2019-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003057A1 true CL2021003057A1 (es) | 2022-09-09 |
Family
ID=70918748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003057A CL2021003057A1 (es) | 2019-05-23 | 2021-11-19 | Formas cristalinas de un inhibidor btk |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3972960A1 (es) |
| JP (1) | JP2022534216A (es) |
| KR (1) | KR20220012280A (es) |
| CN (1) | CN113840821A (es) |
| AR (1) | AR118981A1 (es) |
| AU (1) | AU2020279927A1 (es) |
| BR (1) | BR112021023054A2 (es) |
| CA (1) | CA3137790A1 (es) |
| CL (1) | CL2021003057A1 (es) |
| IL (1) | IL287668A (es) |
| MX (1) | MX2021014157A (es) |
| TW (1) | TW202110811A (es) |
| WO (1) | WO2020234779A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022033569A1 (zh) * | 2020-08-14 | 2022-02-17 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
| TW202245778A (zh) | 2021-01-26 | 2022-12-01 | 瑞士商諾華公司 | 藥物組成物 |
| KR20240055038A (ko) | 2021-09-03 | 2024-04-26 | 노파르티스 아게 | 다발성 경화증 치료를 위한 lou064 |
| WO2023111802A1 (en) | 2021-12-14 | 2023-06-22 | Novartis Ag | Methods of treatment using lou064 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| WO2024069507A1 (en) | 2022-09-30 | 2024-04-04 | Novartis Ag | Synthesis methods and intermediates for the production of remibrutinib |
| CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ525656A (en) | 2000-11-07 | 2004-12-24 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
| TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| US7365096B2 (en) | 2002-12-09 | 2008-04-29 | Board Of Regents, The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
| PE20050158A1 (es) | 2003-05-19 | 2005-05-12 | Irm Llc | Compuestos inmunosupresores y composiciones |
| ZA200602666B (en) | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2020
- 2020-05-20 CA CA3137790A patent/CA3137790A1/en active Pending
- 2020-05-20 BR BR112021023054A patent/BR112021023054A2/pt unknown
- 2020-05-20 CN CN202080036320.6A patent/CN113840821A/zh active Pending
- 2020-05-20 EP EP20729201.2A patent/EP3972960A1/en active Pending
- 2020-05-20 MX MX2021014157A patent/MX2021014157A/es unknown
- 2020-05-20 WO PCT/IB2020/054752 patent/WO2020234779A1/en unknown
- 2020-05-20 JP JP2021569267A patent/JP2022534216A/ja active Pending
- 2020-05-20 KR KR1020217041087A patent/KR20220012280A/ko unknown
- 2020-05-20 AU AU2020279927A patent/AU2020279927A1/en active Pending
- 2020-05-21 AR ARP200101442A patent/AR118981A1/es unknown
- 2020-05-21 TW TW109116921A patent/TW202110811A/zh unknown
-
2021
- 2021-10-28 IL IL287668A patent/IL287668A/en unknown
- 2021-11-19 CL CL2021003057A patent/CL2021003057A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220012280A (ko) | 2022-02-03 |
| JP2022534216A (ja) | 2022-07-28 |
| IL287668A (en) | 2021-12-01 |
| EP3972960A1 (en) | 2022-03-30 |
| AU2020279927A1 (en) | 2022-01-06 |
| MX2021014157A (es) | 2022-01-04 |
| WO2020234779A1 (en) | 2020-11-26 |
| AR118981A1 (es) | 2021-11-17 |
| CA3137790A1 (en) | 2020-11-26 |
| CN113840821A (zh) | 2021-12-24 |
| TW202110811A (zh) | 2021-03-16 |
| BR112021023054A2 (pt) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003057A1 (es) | Formas cristalinas de un inhibidor btk | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CL2021000387A1 (es) | Compuestos de anillo fusionado | |
| PE20181271A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| CL2017003496A1 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. | |
| UY38793A (es) | Compuestos químicos | |
| CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
| UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
| SV2016005312A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer | |
| MX2020013348A (es) | Anticuerpos biespecificos contra dll3-cd3. | |
| CR20190483A (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats | |
| UY35446A (es) | 2?((4?AMINO?3?(3?FLUOR?5?HIDROXIFENIL)?1H?PIRAZOLO[3,4?D]PIRIMIDIN?1?IL)METIL)?5?(3?(2?(2?METOXIETOXI)ETOXI)PROP?1?IN?1?IL)?3?(2?(TRIFLUORMETIL)BENCIL)QUINAZOLIN?4(3H)?ONA COMO INHIBIDOR DUAL DE PI3K d/g | |
| AR107547A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| PL415888A1 (pl) | Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie | |
| CO2021005540A2 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano (thp) | |
| CO2022000260A2 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| CO2023008475A2 (es) | Inhibidores de enzimas | |
| CL2020001818A1 (es) | Compuestos de sililetinilo hetarilo como inhibidores de la nitrificación. | |
| CL2021000254A1 (es) | Formas cristalinas de un inhibidor de lta4h | |
| CO2021004061A2 (es) | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) | |
| BR112022000207A2 (pt) | Formas cristalinas de inibidores de calicreína plasmática | |
| EA202190096A1 (ru) | Композиция, содержащая аналог соматостатина, для радиофармацевтического применения |